期刊文献+

FKBP5对前列腺癌C4-2细胞生长的影响及机制的初步研究 被引量:1

Preliminary study on the effect and mechanism of FKBP5 on prostate cancer C4-2 cells
原文传递
导出
摘要 目的:观察抑制FK506结合蛋白5(FKBP5)基因表达和应用FKBP5的抑制剂FK506对前列腺癌细胞生长的影响,并初步探究其作用机制。方法:利用shRNA和FK506处理前列腺癌C4-2细胞,然后用MTT法检测细胞生长变化情况;通过Western blot检测处理过的C4-2细胞中NF-κB信号通路中相关蛋白的变化。结果:利用shRNA和FK506抑制C4-2细胞中的FKBP5的表达后,MTT法显示实验组细胞的增殖活性明显低于对照组(P<0.05),FK506对细胞生长有明显的抑制作用,并且这种作用具有浓度依赖性。在C4-2细胞系中,降表达FKBP5后发现IκBα表达量增高,磷酸化的NF-κB表达升高,并且胞浆的NF-κB含量增多而细胞核中的NF-κB明显减少。结论:抑制FKBP5的表达可以抑制前列腺癌C4-2细胞系的生长,FKBP5的抑制剂FK506同样可以抑制细胞生长,FKBP5对细胞生长的影响可能是通过调节NF-κB信号通路来实现的,而FKBP5可能是去势抵抗性前列腺癌的一个新的治疗靶点。 Objective:To observe the effect of inhibiting the FKBP5 gene on the growth of prostate cancer cells and explore the mechanism.Method:The growth activity of these cells were detected by MTT assay,after the C4-2 cells were treated by shRNA and FK506.We detected the proteins content change involved in the NF-κB signaling pathway by Western blot.Result:After the expression of FKBP5 was decreased by shRNA or the FKBP5 was inhibited by FK506,the growth of the prostate cancer C4-2 cell decreased significantly compared with the control group by MTT assay(P〈0.05).The inhibition of FK506 for the cell growth had the concentration dependence.In C4-2 cells,we found that the expression of IκBαand the phosphorylated NF-κB increased,after knockout of the FKBP5.Moreover the content of NF-κB in the cytoplasm increased and the NF-κB in the cell nucleus decreased.Conclusion:The growth of C4-2 cell can be inhibited by knockout of FKBP5 and FK506.The effect of FKBP5 on cell growth may involve the NF-κB pathway.FKBP5 may be a new therapeutic target for prostate cancer.
作者 胡斌 尚芝群 牛远杰 HU Bin;SHANG Zhiqun;NIU Yuanjie(Department of Comprehensive Surgery,Tianjin Medical University General Hospital Airport Hospital,Tianjin,300308,China;Tianjin Institute of Urology)
出处 《临床泌尿外科杂志》 2018年第8期638-641,共4页 Journal of Clinical Urology
关键词 前列腺癌 FKBP5 FK506 NF-ΚB prostate cance FKBP5 FKS06 NF-κB
  • 相关文献

参考文献2

二级参考文献16

  • 1赫杰,赵平,陈万青.2011中国肿瘤登记年报.北京:军事医学科学出版社,2012.
  • 2Segi M. Cancer mortality for selected sites in 24 countries ( 1950- 57). Sendai, Japan: Department of Public Health, Tohoku Uni- versity of Medicine: 1960.
  • 3Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer, 2010, 127 : 2893-2917.
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61 : 69-90.
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10-29.
  • 6Peyromaure M, Debre B, Mao K, et al. Management of prostate cancer in China: a muhicenter report of 6 institutions. J Urol, 2005, 174: 1794-1797.
  • 7Taa ZQ, Shi AM, Wang KX, et al. Epidemiology of prostate cancer: current status [ J ]. Eur Rev Med Pharmacol Sei, 2015,19 ( 5 ) : 805- 812.
  • 8Pei H, Li L, Fridley BL, et al. FKBP51 affecls cancer cell response to chemotherapy by negatively regulating Akt [ J ]. Cancer cell, 2009,16 ( 3 ) :259-266.
  • 9Solassol J, Mange A, Maudelonde T. FKBP family proteins as promis- ing new biomarkers for cancer [ J ]. Curr Opin Pharmacol, 2011,11 (4) :320-325.
  • 10Li L,Lou Z,Wang L. The role of FKBP5 in cancer aetiology and che- mocsistance[ J ]. Br J Cancer,2011,104 ( 1 ) : 19-23.

共引文献71

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部